Piramal Pharma Q3 FY25 revenue up 13%
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The company has received the GMP Certification after successful closure of the inspection
Final decision from the European Commission is anticipated within the coming months
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Subscribe To Our Newsletter & Stay Updated